Interleukin 35 Protein (IL35) (AA 21-229, AA 57-253) (Fc Tag)
-
- Target Alle Interleukin 35 (IL35) Proteine anzeigen
- Interleukin 35 (IL35)
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 21-229, AA 57-253
-
Spezies
- Human
-
Quelle
- CHO Cells
- Aufreinigungstag / Konjugat
- Dieses Interleukin 35 Protein ist gelabelt mit Fc Tag.
- Verwendungszweck
- IL-35 (human):Fc (human) (rec.)
- Spezifität
- The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.
- Produktmerkmale
- Protein. The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
- Reinheit
- >98 % (SDS-PAGE)
- Endotoxin-Niveau
- <0.06EU/μg protein (LAL test, Lonza).
- Biological Activity Comment
- Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.
- Top Product
- Discover our top product IL35 Protein
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- Lot specific
- Buffer
- Lyophilized from 0.2μm-filtered solution in PBS.
- Handhabung
- Avoid freeze/thaw cycles.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
-
- Target
- Interleukin 35 (IL35)
- Andere Bezeichnung
- IL-35 (IL35 Produkte)
- Hintergrund
-
Alternate Names/Synonyms: Interleukin-35
Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
- NCBI Accession
- NP_000873
-